JAGSNPHARM
Jagsonpal Pharmaceuticals Limited
Each stock's 10,000-path forecast, rendered as light.
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) Stock Analysis & Case Study
Is JAGSNPHARM a good buy? The data-driven verdict.
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) trades at ₹231,on the numbers it mixed signals, a Downstox Snapshot Score of 46/100.
On the numbers, Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) mixed signals, a Downstox Snapshot Score of 46/100, weighing premium at 32.4× earnings, ROE of 17.3%, a 50% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
JAGSNPHARM fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How JAGSNPHARM ranks against the 2,373 companies in our screener
- JAGSNPHARM's market cap of 1,524 Cr ranks in the 46th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- JAGSNPHARM's book value of ₹41 ranks in the 29th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- JAGSNPHARM's promoter holding of 69.1% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- JAGSNPHARM's 3-year profit (PAT) growth of 16.0% ranks in the 50th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- JAGSNPHARM's 3-year revenue growth of 7.0% ranks in the 41st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- JAGSNPHARM's debt-to-equity ratio of 0.03x is lower than 90% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is JAGSNPHARM overvalued? JAGSNPHARM P/E vs peers
JAGSNPHARM trades at 32.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
JAGSNPHARM share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of JAGSNPHARM history (28%/yr drift, 51%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| JAGSNPHARM 2027 | ₹122 | ₹232 | ₹441 | +0% |
| JAGSNPHARM 2028 | ₹93 | ₹233 | ₹582 | +1% |
| JAGSNPHARM 2029 | ₹77 | ₹234 | ₹713 | +1% |
| JAGSNPHARM 2030 | ₹62 | ₹235 | ₹887 | +2% |
| JAGSNPHARM 2031 | ₹56 | ₹236 | ₹1,004 | +2% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability JAGSNPHARM goes up, or doubles?
The bull case for JAGSNPHARM
- JAGSNPHARM's return on equity of 17.3% ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- JAGSNPHARM's return on capital employed of 22.7% ranks in the 85th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹713.
The bear case & risks
- JAGSNPHARM's P/E of 32.4x is lower than 43% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (51%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹77.
JAGSNPHARM volatility & expected range, how bumpy is the ride?
Over the last 9.8 years JAGSNPHARM compounded at 28%/year with annualized volatility of 51%. That volatility implies a 1-year 80% range of ₹122-₹441, the honest backbone behind any single price target.
JAGSNPHARM price forecast, the full 60-month probability fan
JAGSNPHARM price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds JAGSNPHARM hits common targets within the simulated horizon?
Full multi-horizon detail on the JAGSNPHARM price target & forecast page.
JAGSNPHARM Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. JAGSNPHARM scores 6/8, mixed financial health.
JAGSNPHARM MTF margin & leverage across 9 brokers
Margin Trading Facility lets you buy JAGSNPHARM with part of the capital. Lower margin % = higher leverage. Rates compared across 9 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 34.46% | 2.9× |
| Groww | 34.59% | 2.9× |
| Dhan | 40.00% | 2.5× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 34.61% | 2.9× |
| Pocketful | 34.85% | 2.9× |
| Anand RathiCHEAPEST | 34.46% | 2.9× |
| Bajaj Broking | 50.00% | 2.0× |
| Share India | 34.57% | 2.9× |
Compare every broker on the JAGSNPHARM MTF page.
About Jagsonpal Pharmaceuticals Limited: sector, index & market-cap context
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) is a small-cap NSE-listed company, with a market capitalisation of ₹1,524 Cr. See more stocks on our screener.
How the JAGSNPHARM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Jagsonpal Pharmaceuticals Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
JAGSNPHARM analysis, FAQs
Is Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) a good buy?
On the numbers, Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) mixed signals, a Downstox Snapshot Score of 46/100, weighing premium at 32.4× earnings, ROE of 17.3%, a 50% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is JAGSNPHARM overvalued or undervalued?
JAGSNPHARM trades at 32.4× earnings, premium versus the ~22× long-run Nifty average.
What is the JAGSNPHARM share price target for 2031?
JAGSNPHARM's probability-weighted 2031 median target is ₹236, with an 80% range of ₹56-₹1,004 (10,000-path Monte-Carlo).
What is the probability JAGSNPHARM doubles in 5 years?
The modelled probability of JAGSNPHARM reaching ₹462 (2×) within 5 years is 28%.
What is the bull case for JAGSNPHARM?
JAGSNPHARM's return on equity of 17.3% ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. JAGSNPHARM's return on capital employed of 22.7% ranks in the 85th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in JAGSNPHARM?
JAGSNPHARM's P/E of 32.4x is lower than 43% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (51%/yr) means a wide, bumpy range of outcomes, size positions accordingly.